(R)-arylalkylamino derivatives and pharmaceutical compositions containing them

(R)-Arylalkylamino derivatives of formula (I):

• wherein
• R is selected from:
• 2-thiazolyl or 2-oxazolyl, unsubstituted or substituted by a methyl, tert-butyl or trifluoromethyl group;
• C(Ra)═N—W wherein W is linear or branched C1-C4 alkyl, or
• CORa, SORa, or SO2Ra,
• wherein
• Ra is selected from
• C1-C5-alkyl, C3-C6-cycloalkyl, C2-C5-alkenyl, or phenyl unsubstituted or substituted with a group selected from halogen, C1-C4-alkyl, C1-C4-alkoxy, halo-C1-C4-alkoxy, hydroxy, C1-C4-acyloxy, phenoxy, cyano, nitro, or amino;
• a heteroaryl group selected from pyridine, pyrimidine, pyrrole, thiophene, furan, indole, thiazole, or oxazole, such heteroaryl being unsubstituted or substituted with a group selected from halogen, C1-C4-alkyl, C1-C4-alkoxy, halo-C1-C4-alkoxy, hydroxy, C1-C4-acyloxy, phenoxy, cyano, nitro, or amino;
• an α or β carboxyalkyl residue of straight or branched C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, or C1-C6-phenylalkyl, optionally substituted with a further carboxy (COOH) group;
• or
• an ω-aminoalkylamino group of formula II:
• wherein
• X represents:
• linear or branched C1-C6 alkylene, C4-C6 alkenylene, C4-C6 alkynylene, optionally substituted by a CO2R4 group or by a CONHR5 group, wherein R4 represents hydrogen or a linear or branched C1-C4 alkyl group or a linear or branched C2-C6 alkenyl group, and wherein R5 represents hydrogen, linear or branched C2-C6 alkyl or an OR4 group, R4 being defined as above;
• or
• a (CH2)m—B—(CH2)n, group, optionally substituted by a CO2R4 or CONHR5 group, as defined above, wherein B is an oxygen, sulfur, or nitrogen atom optionally substituted by a C1-C4 alkyl group, m is zero or an integer from 2 to 3 and n is an integer from 2 to 3, or B is a CO, SO, or CONH group, m is an integer from 1 to 3 and n is an integer from 2 to 3;
• or X together with the nitrogen atom to which it is bound and with the R2 group forms a nitrogen containing 3-7 membered heterocyclic, monocyclic or polycyclic ring, and R3 represents hydrogen, C1-C4 alkyl, C1-C4 acyl, or phenyl unsubstituted or substituted with a group selected from halogen, C1-C4-alkyl, C1-C4-alkoxy, hydroxy, C1-C4-acyloxy, phenoxy, cyano, nitro, or amino;
• R2 and R3 are independently:
• hydrogen, linear or branched C1-C6 alkyl, optionally interrupted by an oxygen or sulfur atom, C3-C7 cycloalkyl, C3-C6 alkenyl, C3-C6-alkynyl, aryl-C1-C3-alkyl, or hydroxy-C2-C3-alkyl group;
• or R2 and R3 together with the N atom to which they are bound, form a 3-7 membered nitrogen heterocyclic ring of formula (III)
• wherein
• Y represents:
• a single bond, CH2, O, S, or a N—R6 group, where R6 represents hydrogen, C1-C4 alkyl, C1-C4 acyl, or phenyl unsubstituted or substituted with a group selected from halogen, C1-C4-alkyl, C1-C4-alkoxy, hydroxy, C1-C4-acyloxy, phenoxy, cyano, nitro, or amino, and p represents an integer from 0 to 3;
• or
• a residue of formula SO2R7 wherein R7 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, aryl or heteroaryl;
• R1 is linear or branched C1-C5 alkyl, or C3-C5 cycloalkyl;
• and
• Ar is 3′-benzoylphenyl, 3′-(4-chloro-benzoyl)-phenyl, 3′-(4-methyl-benzoyl)-phenyl, 3′-acetyl-phenyl, 3′-propionyl-phenyl, 3′-isobutanoyl-phenyl, 4′-trifluoromethanesulfonyloxy-phenyl, 4′-benzenesulfonyloxy-phenyl, 4′-trifluoromethanesulfonylamino-phenyl, 4′-benzenesulfonylamino-phenyl, 4′-benzenesulfonylmethyl-phenyl, 4′-acetoxyphenyl, 4′-propionyloxy-phenyl, 4′-benzoyloxy-phenyl, 4′-benzoylamino-phenyl, 3′-(furan-2-carbonyl)-phenyl, 3′-(benzofuran-2-carbonyl)-phenyl, 3′-(thiophene-2-carbonyl)-phenyl;
• 3′-(pyridine-2-carbonyl)-phenyl, 3′-(thiazole-2-carbonyl)-phenyl, 3′-(oxazole-2-carbonyl)-phenyl;
• 3′-(2-furyl)-phenyl, 3′-(2-oxazolyl)-phenyl, 3′-(3-isoxazolyl)-phenyl, 3′-(2-benzoxazolyl)-phenyl, 3′-(3-benzoisoxazolyl)-phenyl, 3′-(2-thiazolyl)-phenyl, 3′-(2-pyridyl)-phenyl, or 3′-(2-thienyl)-phenyl;
• or Ar is a heteroaryl ring selected from pyridine, pyrrole, thiophene, furan, or indole.